TransCode Therapeutics to Present Updated Phase 1a TTX-MC138 Data at ESMO Congress 2026

TransCode Therapeutics will present updated Phase 1a clinical data for its lead candidate TTX-MC138, a therapy targeting miR-10b in advanced solid tum...